What Nurix Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 15 | 48 |
| Total trades | 31 | 105 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 74,844 | 295,015 |
| Disposed | 70,744 | 289,652 |
| Net activity | +4,100 | +5,363 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer | Nov 04 | Open-market sale · S | −1,469 | $16.20 | −$23.8K | 42,745 |
| van Houte Hans | Chief Financial Officer | Nov 04 | Open-market sale · S | −3,300 | $15.38 | −$50.8K | 44,214 |
| Ring Christine | Chief Legal Officer | Nov 03 | Open-market sale · S | −6,113 | $25.83 | −$158K | 4,406 |
| Ring Christine | Chief Legal Officer | Nov 02 | Open-market sale · S | −1,075 | $26.76 | −$28.8K | 10,519 |
| Ring Christine | Chief Legal Officer | Nov 02 | Open-market sale · S | −9,527 | $25.74 | −$245K | 11,594 |
| Ring Christine | Chief Legal Officer | Nov 02 | Exercise / conversion · M | +5,786 | $8.72 | +$50.5K | 21,121 |
| Hansen Gwenn | Chief Scientific Officer | Nov 02 | Open-market sale · S | −1,452 | $26.80 | −$38.9K | 123,452 |
| Hansen Gwenn | Chief Scientific Officer | Nov 02 | Exercise / conversion · M | +1,452 | $1.86 | +$2.7K | 124,904 |
| Ring Christine | Chief Legal Officer | Oct 30 | Open-market sale · S | −3,957 | $26.28 | −$104K | 15,335 |
| Ring Christine | Chief Legal Officer | Oct 30 | Exercise / conversion · M | +3,573 | — | — | 19,292 |
| Ring Christine | Chief Legal Officer | Oct 30 | Exercise / conversion · M | +2,859 | — | — | 15,719 |
| Ring Christine | Chief Legal Officer | Oct 30 | Exercise / conversion · M | +3,750 | — | — | 12,860 |
| van Houte Hans | Chief Financial Officer | Oct 30 | Open-market sale · S | −2,834 | $26.28 | −$74.5K | 47,514 |
| van Houte Hans | Chief Financial Officer | Oct 30 | Exercise / conversion · M | +3,573 | — | — | 50,348 |
| van Houte Hans | Chief Financial Officer | Oct 30 | Exercise / conversion · M | +2,859 | — | — | 46,775 |
| van Houte Hans | Chief Financial Officer | Oct 30 | Exercise / conversion · M | +3,750 | — | — | 43,916 |
| Hansen Gwenn | Chief Scientific Officer | Oct 30 | Open-market sale · S | −3,957 | $26.28 | −$104K | 123,452 |
| Hansen Gwenn | Chief Scientific Officer | Oct 30 | Exercise / conversion · M | +3,573 | — | — | 127,409 |
| Hansen Gwenn | Chief Scientific Officer | Oct 30 | Exercise / conversion · M | +2,859 | — | — | 123,836 |
| Hansen Gwenn | Chief Scientific Officer | Oct 30 | Exercise / conversion · M | +3,750 | — | — | 120,977 |
Loading...